药物相关中枢神经系统血管炎与可逆性脑血管收缩综合征:WHO药物警戒数据库的全球不成比例分析
本研究基于WHO全球药物警戒数据库VigiBase(2025年6月提取),采用病例-非病例设计,识别与中枢神经系统血管炎(CNSV)和可逆性脑血管收缩综合征(RCVS)不成比例关联的药物。共识别735例CNSV和1553例RCVS病例,CNSV主要与免疫检查点抑制剂和抗甲状腺药物相关,RCVS主要与5-羟色胺能及血管活性药物相关,且RCVS发病时间更短。
要点
- CNSV主要与帕博利珠单抗、纳武利尤单抗和丙硫氧嘧啶相关,中位发病时间35.50天。
- RCVS主要与曲普坦类、麦角衍生物、SSRIs和大麻相关,中位发病时间8.75天。
- 替普罗木单抗(teprotumumab)显示最强RCVS信号(6例;aROR 60.17,95%CI 18.66-194.05)。
核心结论
- 药物相关CNSV和RCVS具有不同的药理和时间特征,有助于指导停药决策和神经血管急症管理。
研究设计与样本
- 基于VigiBase(2025年6月提取)的病例-非病例研究,计算未调整和调整报告比值比(aROR),调整年龄、性别、地理区域和报告特征。
- 共识别735例CNSV病例和1553例RCVS病例,并分析发病时间、停药结局和病死率。
主要发现
- CNSV主要与免疫检查点抑制剂(帕博利珠单抗和纳武利尤单抗)和抗甲状腺药物(丙硫氧嘧啶)相关,中位发病时间35.50天(IQR 7.75-123.25)。
- RCVS主要与5-羟色胺能和血管活性药物(曲普坦类、麦角衍生物、SSRIs和大麻)相关,中位发病时间8.75天(IQR 3.25-52.88)。
- 替普罗木单抗(IGF-1R抑制剂,用于甲状腺眼病)显示最强RCVS信号(6例;aROR 60.17,95%CI 18.66-194.05)。
- 女性性别与RCVS独立相关(aROR 2.57,95%CI 2.23-2.97)。
临床怎么用
- 临床遇到CNSV或RCVS时应审查用药史,尤其免疫检查点抑制剂、抗甲状腺药物、曲普坦类、麦角衍生物、SSRIs和大麻。
- RCVS发病时间较短(中位8.75天),用药初期需警惕神经血管急症症状。
- 替普罗木单抗相关RCVS信号强,使用该药患者出现神经系统症状时应及时评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to identify and characterize drugs disproportionately associated with central nervous system vasculitis (CNSV) and reversible cerebral vasoconstriction syndrome (RCVS) in VigiBase, the World Health Organization (WHO) global pharmacovigilance database, and to describe their pharmacological and temporal profiles. METHODS: We conducted a case-non-case study in VigiBase, the WHO global pharmacovigilance database (extract June 2025). Both unadjusted and adjusted reporting odds ratios (aROR) were estimated, the latter using multivariate logistic regression accounting for age, sex, geographic region and reporting characteristics. Time-to-onset, dechallenge outcomes and fatality rates were also analysed. RESULTS: We identified 735 CNSV cases and 1553 RCVS cases. CNSV was predominantly associated with immune checkpoint inhibitors (pembrolizumab and nivolumab) and antithyroid drugs (propylthiouracil), with a median time-to-onset of 35.50 days (interquartile range [IQR] 7.75-123.25). RCVS was primarily associated with serotonergic and vasoactive agents (triptans, ergot derivatives, selective serotonin reuptake inhibitors [SSRIs] and cannabis), with a markedly shorter onset of 8.75 days (IQR 3.25-52.88). The strongest RCVS signal was a novel association with teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor approved for thyroid eye disease (6 cases; aROR 60.17, 95% confidence interval [CI] 18.66-194.05). Female sex was independently associated with RCVS (aROR 2.57, 95% CI 2.23-2.97). CONCLUSIONS: Drug-associated CNSV and RCVS exhibit distinct pharmacological and temporal profiles, which may help inform drug withdrawal decisions and optimal management of these neurovascular emergencies.
引用
- Chretien B, Deshayes S, Muraoka S, et al. Drug-associated central nervous system vasculitis and reversible cerebral vasoconstriction syndrome: A global disproportionality analysis of the WHO pharmacovigilance database (VigiBase). Br J Clin Pharmacol. 2026. PMID: 42706935. doi:10.1002/bcp.70789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。